Intravenous (IV) Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
Bladder cancer is a common disease with high rates of mortality, especially at advanced
stages. Neo-adjuvant cisplatin-based chemotherapy (NAC) followed by radical cystectomy is
considered standard of care for patients with muscle invasive disease, as NAC improves
surgical outcomes in these patients. However, some patients are ineligible for
cisplatin-based chemotherapy due to other medical issues. Although a combination of
carboplatin and gemcitabine has been used with limited success, most patients proceed
directly to cystectomy without realizing the potential survival benefit afforded by NAC.
Intravenous ascorbate (vitamin C) administration (IVC) has been shown to improve both
carboplatin and gemcitabine-based therapy in other models. This trial will add IVC to
gemcitabine/carboplatin chemotherapy to evaluate whether co-treatment will increase
therapeutic efficacy.